JNJ - JOHNSON & JOHNSON
Close
143.56
-0.255 -0.178%
Share volume: 167,162
Last Updated: Mon 06 Jan 2025 08:30:05 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$143.82
-0.26
-0.18%
View ratios
| Fiscal Date | 2023-04-02 | 2023-07-02 | 2023-10-01 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2023-04-28 | 2023-07-31 | 2023-10-27 | 2024-02-16 | 2024-05-01 | 2024-07-25 | |
| Total revenue | 24.746 B | 25.530 B | 21.351 B | 13.532 B | 21.383 B | 22.447 B | |
| Cost of revenue | 8.395 B | 8.212 B | 6.606 B | 3.340 B | 6.511 B | 6.869 B | |
| Gross profit | 16.351 B | 17.318 B | 14.745 B | 10.192 B | 14.872 B | 15.578 B | |
| 5.91% | -14.86% | -30.88% | 45.92% | 4.75% | |||
| Operating expenses | 9.701 B | 10.494 B | 8.847 B | 7.555 B | 8.799 B | 9.121 B | |
| Selling general and admin | 6.138 B | 6.665 B | 5.400 B | 3.309 B | 5.257 B | 5.681 B | |
| Research and development | 3.563 B | 3.829 B | 3.447 B | 4.246 B | 3.542 B | 3.440 B | |
| Total expenses | 18.096 B | 18.706 B | 15.453 B | 10.895 B | 15.310 B | 15.990 B | |
| 3.37% | -17.39% | -29.50% | 40.52% | 4.44% | |||
| Operating income | 6.650 B | 6.824 B | 5.898 B | 2.637 B | 6.073 B | 6.457 B | |
| Ebit | 6.650 B | 6.824 B | 5.898 B | 2.637 B | 6.073 B | 6.457 B | |
| Pretax income | -737.000 M | 6.762 B | 5.217 B | 3.820 B | 3.714 B | 5.748 B | |
| -1,017.50% | -22.85% | -26.78% | -2.77% | 54.77% | |||
| Income tax | -669.000 M | 1.618 B | 908.000 M | -121.000 M | 459.000 M | 1.062 B | |
| Net income basic | -68.000 M | 5.144 B | 26.028 B | 4.049 B | 3.255 B | 4.686 B | |
| 7,664.71% | 405.99% | -84.44% | -19.61% | 43.96% | |||
| Net income | -68.000 M | 5.144 B | 26.028 B | 4.049 B | 3.255 B | 4.686 B | |
| 7,664.71% | 405.99% | -84.44% | -19.61% | 43.96% |